Pfizer, Inc. (NYSE:PFE) – Investment analysts at SunTrust Banks raised their Q3 2017 earnings estimates for Pfizer in a research report issued on Monday. SunTrust Banks analyst J. Boris now expects that the biopharmaceutical company will earn $0.65 per share for the quarter, up from their prior forecast of $0.61.
A number of other brokerages have also issued reports on PFE. Cowen and Company set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Monday, August 14th. Jefferies Group LLC set a $35.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a report on Thursday, August 24th. Berenberg Bank reissued a “hold” rating and issued a $36.00 price objective (down previously from $39.00) on shares of Pfizer in a report on Tuesday, August 15th. Deutsche Bank AG set a $38.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, October 11th. Finally, BidaskClub lowered shares of Pfizer from a “sell” rating to a “strong sell” rating in a report on Thursday, July 13th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $38.15.
TRADEMARK VIOLATION NOTICE: This article was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2017/10/28/suntrust-banks-weighs-in-on-pfizer-inc-s-q3-2017-earnings-pfe.html.
Shares of Pfizer (NYSE PFE) opened at 35.83 on Wednesday. Pfizer has a one year low of $29.83 and a one year high of $36.60. The company’s 50-day moving average is $35.41 and its 200-day moving average is $33.80. The company has a market cap of $213.09 billion, a price-to-earnings ratio of 26.21 and a beta of 1.00.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The firm had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same quarter last year, the business earned $0.64 EPS. The business’s revenue was down 1.9% on a year-over-year basis.
A number of large investors have recently modified their holdings of PFE. Howe & Rusling Inc. raised its holdings in Pfizer by 7.2% in the first quarter. Howe & Rusling Inc. now owns 363,501 shares of the biopharmaceutical company’s stock valued at $12,435,000 after acquiring an additional 24,439 shares in the last quarter. OLD Second National Bank of Aurora raised its holdings in Pfizer by 0.3% in the first quarter. OLD Second National Bank of Aurora now owns 114,947 shares of the biopharmaceutical company’s stock valued at $3,932,000 after acquiring an additional 323 shares in the last quarter. Edmp Inc. acquired a new stake in Pfizer in the first quarter valued at approximately $3,573,000. Asset Planning Services Ltd. raised its holdings in Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after acquiring an additional 137 shares in the last quarter. Finally, First United Bank Trust raised its holdings in Pfizer by 17.5% in the first quarter. First United Bank Trust now owns 9,668 shares of the biopharmaceutical company’s stock valued at $331,000 after acquiring an additional 1,437 shares in the last quarter. 68.98% of the stock is currently owned by hedge funds and other institutional investors.
In related news, insider Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total value of $249,900.00. Following the sale, the insider now owns 132,124 shares of the company’s stock, valued at $4,492,216. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the completion of the sale, the insider now directly owns 151,474 shares in the company, valued at approximately $5,074,379. The disclosure for this sale can be found here. Insiders have sold 464,521 shares of company stock worth $15,813,961 in the last three months. Corporate insiders own 0.06% of the company’s stock.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be given a dividend of $0.32 per share. The ex-dividend date is Thursday, November 9th. This represents a $1.28 annualized dividend and a dividend yield of 3.57%. Pfizer’s dividend payout ratio is presently 94.12%.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.